Skip Ribbon Commands
Skip to main content

Liver disease and the rise of hepatitis due to the opioid crisis

Liver disease and the rise of hepatitis due to the opioid crisis were just a few of the discussion topics when James Trotter, MD – Medical Director, Transplant Hepatology at Baylor University Medical Center met in Washington D.C. with Rep. Pete Sessions from the 32nd Congressional district. [...]

New Medicine Could Melt Away Fat

James Trotter, MD, Medical Director, Transplant Hepatology at Baylor University Medical Center is one of the chief investigators of a new therapy that could revolutionize how fatty liver disease is managed. [...]

Baylor Leads The Way In Studies To Combat The Toll Of Fatty Liver Disease

Liver disease is on the rise among middle-aged Americans. The Centers for Disease Control and Prevention (CDC) reports that fatty liver disease, viral hepatitis, and alcoholic liver disease are the major contributors to a rise in liver-disease-related deaths and liver cancer in people ages 45-64. [...]

Novel Technology Reduces Need For Liver Biopsies

Detecting and staging hepatic fibrosis is important in the treatment of chronic liver diseases that can progress to cirrhosis. Liver biopsy is the standard method of detecting and staging fibrosis but a new, noninvasive alternative is now in use at BUMC [...]

Living Donor Study

Baylor University Medical Center is one of 16 sites nationwide participating in a pilot study to determine how living donor transplant candidates fare after transplant, whether they actually donate or not. [...]

Liver Outreach Clinics Continue To Expand

Patients with liver disease who live miles from Baylor University Medical Center (BUMC) and Baylor Scott & White All Saints Medical Center – Fort Worth (BSWASMC) benefit greatly from having access to liver outreach clinics in their communities. [...]

Non-Alcoholic Fatty Liver Disease or NAFLD

Estimates show that 20 to 30 percent of the U.S. population has a non-alcoholic fatty liver disease or NAFLD. NAFLD is a broad term used to describe a spectrum of liver diseases with evidence of steatosis (or fat) in the liver once other causes of fatty liver, such as medications [...]

New Hepatitis C Drugs, Sofosbuvir and Simeprevir

Two new drugs are providing hope to the approximately 3.2 million people in the United States who are infected with the hepatitis C virus. Unlike the previous therapy, the new drugs have minimal side effects and offer most patients an almost 90 percent chance at a cure in just 12 weeks. [...]

Hepatic Elastography and Liver Disease

MR-based hepatic elastography involves mechanical stimulation of the liver to determine liver stiffness, which can be used as an index for how much fibrosis is present. [...]

Transplant Hepatology Fellowship Program

The liver transplant program at the Annette C. and Harold C. Transplant Institute at Baylor University Medical Center at Dallas and Baylor Scott & White All Saints Medical Center at Fort Worth is the fifth largest in the United States. [...]

Hepatitis C, a Silent Killer, Meets Its Match

Medicine may be on the brink of an enormous public health achievement: turning the tide against hepatitis C, a silent plague that kills more Americans annually than AIDS and is the leading cause of liver transplants. If the effort succeeds, it will be an unusual conquest of a viral epidemic [...]

New Hepatitis C Treatment

There are 3 million Americans infected with Hepatitis C, and three out of four of them are baby boomers. Most of them contracted the disease without knowing it. But there is a new treatment that was just approved by the FDA. [...]

Clinical Studies

Our team of hepatologists play an integral role in the development of select clinical studies of approved antiviral medications to treat hepatitis C and hepatitis B. More than 40 drug trials designed to treat or cure the hepatitis C virus are currently underway at Baylor Dallas and [...]

Incidence of Liver Disease Underestimated

According to the National Center for Health Statistics (NCHS), chronic liver disease and cirrhosis is the 12(th) leading cause of death in the United States. However, this single descriptor might not adequately enumerate all deaths from liver disease. The aim of our study was to update data on [...]

​​​​​